OraSure Q2 Revenue Beats, Guides Q3 Above Street; Gross Margin Expands
OSUR sits 100% above its 52-week low of $2.08 on light trading volume (0.4× avg).
Summary
OraSure delivered Q2 revenue of $30.6M, beating the lone analyst estimate by 5%, while adjusted operating loss of $14.7M was significantly narrower than the $19.8M consensus. Gross margin expanded 140 bps to 43.5%, driven by higher syphilis and Sickle SCAN sales. The company guided Q3 revenue to $29.5M-$32.5M, above the pre-release consensus of $29.06M, signaling continued momentum. This follows a Q1 marked by revenue decline and widened losses, making the beat and margin improvement a notable inflection. The $2M in buybacks adds modest support, but the real story is the operational turnaround and FDA-cleared product pipeline starting to contribute.
At the time of this announcement, OSUR was trading at $4.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $285.7M. The 52-week trading range was $2.08 to $4.58. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.